Chinese clinical oncology · 2026
Role of androgen receptor signaling in chemoresistance in urothelial cancer: a narrative review.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Akai Taro, Yamamichi Gaku, Miyamoto Hiroshi
Аннотация
BACKGROUND AND OBJECTIVE: Intravesical instillation of chemotherapeutic drugs remains a cornerstone in the management of non-muscle-invasive bladder tumor following transurethral surgery, where they are routinely employed to prevent disease recurrence and progression. In patients with locally advanced or metastatic urothelial carcinoma, cisplatin-based combination chemotherapy continues to represent the standard systemic treatment and has also been used in the neoadjuvant setting prior to radical cystectomy. Despite these established strategies, a substantial proportion of these patients exhibit intrinsic or acquired resistance to chemotherapeutic regimens, ultimately leading to poor oncologic outcomes, although the molecular mechanisms underlying chemoresistance remain only partially understood. Meanwhile, accumulating evidence has increasingly suggested a critical role of androgen receptor (AR) signaling in promoting not only the development and progression of urothelial cancer but also resistance to conventional non-surgical therapy for bladder cancer. In this review article, we aim to summarize available data suggesting that AR is involved in chemosensitivity in urothelial cancer.
METHODS: We searched five scholarly databases [PubMed, Embase, Scopus, Google Scholar, and World Health Organization (WHO) Global Index Medicus], using the relevant keywords variably combined. Studies published in English from January 1950 to January 2026 were considered.
KEY CONTENT AND FINDINGS: This article focuses on synthesizing current knowledge regarding the involvement of AR in modulating the efficacy of chemotherapeutic agents used for bladder cancer and discusses their potential of overcoming chemoresistance. Several potential downstream effectors of AR signaling, which increase or decrease chemosensitivity, have also been identified.
CONCLUSIONS: Available data may indicate that therapeutic strategies incorporating anti-AR therapy, apart from its direct anti-tumor activity, may hold considerable promise as a sensitizer of chemotherapy in patients with urothelial cancer.
METHODS: We searched five scholarly databases [PubMed, Embase, Scopus, Google Scholar, and World Health Organization (WHO) Global Index Medicus], using the relevant keywords variably combined. Studies published in English from January 1950 to January 2026 were considered.
KEY CONTENT AND FINDINGS: This article focuses on synthesizing current knowledge regarding the involvement of AR in modulating the efficacy of chemotherapeutic agents used for bladder cancer and discusses their potential of overcoming chemoresistance. Several potential downstream effectors of AR signaling, which increase or decrease chemosensitivity, have also been identified.
CONCLUSIONS: Available data may indicate that therapeutic strategies incorporating anti-AR therapy, apart from its direct anti-tumor activity, may hold considerable promise as a sensitizer of chemotherapy in patients with urothelial cancer.